Status:
WITHDRAWN
Assess Increased Mortality Risk With Each Year of Delayed Tobramycin Solution (TIS) Initiation, and Effect of TIS on Mortality Across Study Centers
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Cystic Fibrosis
Eligibility:
All Genders
6+ years
Brief Summary
Using CFF registry data, this analysis will: describe patterns of time to TIS initiation from first year of TIS eligibility, estimate the increased risk of death attributable to each year of delayed T...
Eligibility Criteria
Inclusion
- ≥6 years of age with a documented Cystic fibrosis (CF) diagnosis,
- moderate-to-severe lung disease,
- Pseudomonas aeruginosa (PA) airway infection.
Exclusion
- Other protocol-defined inclusion/exclusion criteria may apply.
Key Trial Info
Start Date :
March 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01460849
Start Date
March 1 2011
End Date
March 1 2011
Last Update
December 7 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.